Gene: BRAF ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
BRAF
T 0.800 GeneticVariation CLINVAR Targeted therapy for BRAFV600E malignant astrocytoma. 22038996

2011
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Future clinical trials should address whether BRAF (V600E) mutant brain tumor patients will benefit from BRAF (V600E)-directed targeted therapies. 21274720

2011
dbSNP: rs121913377
rs121913377
BRAF
0.100 GeneticVariation BEFREE Future clinical trials should address whether BRAF (V600E) mutant brain tumor patients will benefit from BRAF (V600E)-directed targeted therapies. 21274720

2011
dbSNP: rs113488022
rs113488022
BRAF
T 0.800 GeneticVariation CLINVAR Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. 22586120

2012
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE An activating mutation of BRAF (BRAF-V600E) has been reported in a subset of malignant brain tumors. 24721513

2014
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Future clinical trials should address whether BRAF V600E mutant brain tumour patients will benefit from BRAF V600E-directed targeted therapies. 24353007

2014
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE PKM2-regulated MLC2 phosphorylation, which is greatly enhanced by EGF stimulation or EGFRvIII, K-Ras G12V and B-Raf V600E mutant expression, plays a pivotal role in cytokinesis, cell proliferation and brain tumour development. 25412762

2014
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE BRAF V600E-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS) tumors, but with increased prevalence in the pediatric population and in certain brain tumor subtypes. 24725538

2014
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors. 25484091

2014
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors. 24823863

2014
dbSNP: rs121913377
rs121913377
BRAF
0.100 GeneticVariation BEFREE BRAF V600E-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS) tumors, but with increased prevalence in the pediatric population and in certain brain tumor subtypes. 24725538

2014
dbSNP: rs121913377
rs121913377
BRAF
0.100 GeneticVariation BEFREE Future clinical trials should address whether BRAF V600E mutant brain tumour patients will benefit from BRAF V600E-directed targeted therapies. 24353007

2014
dbSNP: rs121913377
rs121913377
BRAF
0.100 GeneticVariation BEFREE Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors. 24823863

2014
dbSNP: rs121913377
rs121913377
BRAF
0.100 GeneticVariation BEFREE An activating mutation of BRAF (BRAF-V600E) has been reported in a subset of malignant brain tumors. 24721513

2014
dbSNP: rs121913377
rs121913377
BRAF
0.100 GeneticVariation BEFREE PKM2-regulated MLC2 phosphorylation, which is greatly enhanced by EGF stimulation or EGFRvIII, K-Ras G12V and B-Raf V600E mutant expression, plays a pivotal role in cytokinesis, cell proliferation and brain tumour development. 25412762

2014
dbSNP: rs121913377
rs121913377
BRAF
0.100 GeneticVariation BEFREE Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors. 25484091

2014
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Among brain tumors, the BRAF (V600E) mutation is frequently associated with pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas (GGs). 26264609

2015
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing. 25346165

2015
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE The BRAF V600E mutation occurs frequently in certain brain tumors such as pleomorphic xanthoastrocytoma, ganglioglioma, and pilocytic astrocytoma, and less frequently in epithelioid and giant cell glioblastoma. 25885250

2015
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE The patient's resected brain tumor is BRAF V600E mutated, NRAS wild type (WT), and TERT C250T mutated. 26597176

2015
dbSNP: rs121913377
rs121913377
BRAF
0.100 GeneticVariation BEFREE The patient's resected brain tumor is BRAF V600E mutated, NRAS wild type (WT), and TERT C250T mutated. 26597176

2015
dbSNP: rs121913377
rs121913377
BRAF
0.100 GeneticVariation BEFREE Among brain tumors, the BRAF (V600E) mutation is frequently associated with pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas (GGs). 26264609

2015
dbSNP: rs121913377
rs121913377
BRAF
0.100 GeneticVariation BEFREE The BRAF V600E mutation occurs frequently in certain brain tumors such as pleomorphic xanthoastrocytoma, ganglioglioma, and pilocytic astrocytoma, and less frequently in epithelioid and giant cell glioblastoma. 25885250

2015
dbSNP: rs121913377
rs121913377
BRAF
0.100 GeneticVariation BEFREE An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing. 25346165

2015
dbSNP: rs113488022
rs113488022
BRAF
T 0.800 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016